[ad_1]
Vaccines, combined with other public health measures, are ending the acute phase of the coronavirus pandemic and accelerating economic recovery, said Hans Kluge, head of the European Office of the World Health Organization.
Vaccines against the coronavirus will have “phenomenal prospects.” This was announced on December 3 by the head of the European Office of the World Health Organization, Hans Kluge, said the press service of the Office.
According to Kluge, the prospects for vaccines could be “a game changer.”
“Vaccines, when combined with other public health measures, can end the acute phase of the pandemic and accelerate economic recovery. But this can only be done if we ensure that no one is left behind and that all countries and communities can benefit from access to this rescue technology. “, – said Kluge.
He stressed that supplies will be limited and countries must decide who to vaccinate first.
“Our recommendations are that health and social workers, people over 60, residents and long-term care staff should have priority access to COVID-19 vaccines in the context of limited supply. diseases, in addition to the size and proportion of each priority group, countries may decide to prioritize more than one group at a time during the initial phase of immunization, ”said the head of the office.
Kluge noted that it is important not to abandon other measures against the epidemic with the arrival of the vaccine.
“The vaccine is very promising, but its full potential will not be realized without serious will and public approval. But let’s also be clear: there is no vaccine today, not everyone will receive it when it arrives, so it is imperative that we continue to practice basic defenses. behavioral methods (eg wearing masks), “he said.
An outbreak of coronavirus infection began in late 2019 in China. March 11, 2020 World Health Organization declared the spread of the coronavirus a pandemic.
By information World Health Organization on December 2, the world’s 51 vaccine manufacturers are candidates for clinical evaluation. 163 companies are conducting preclinical trials. The American company Moderna reported that the effectiveness of its vaccine against COVID-19 was 94.1% and against the severe form of coronavirus infection, 100%. Preliminary results of the trials of the American vaccine Pfizer, developed jointly with the German BioNTech, showed an effectiveness of more than 90% in the third phase of clinical trials. On November 18, Pfizer announced that the vaccine was 95% effective.
Some countries, notably Turkey and the United Kingdom, are ready to start vaccinations in December 2020.
